These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
In Vivo Albumin-Binding of a C-Functionalized Cyclam Platform for 64Cu-PET/CT Imaging in Breast Cancer Model
preprintsubmitted on 24.07.2020, 14:01 and posted on 27.07.2020, 10:40 by Thomas Le Bihan, Cathryn H.S. Driver, Thomas Ebenhan, Nathalie Le Bris, Jan Rijn Zeevaart, Raphael Tripier
In the aim to design small molecules capable of binding in vivo to albumin to form bioconjugates, a second generation GluCAB derivative(Glucose-Chelator-Albumin Bioconjugate) has been synthesized and studied for in vivo 64Cu-PET/CT imaging in breast cancer mice models together with its first-generation analogue. This series of radioligands - also capable of complexing therapeutic isotopes and therefore classified as theranostic agents - are working on the principle of tumor targeting through the Enhanced Permeability and Retention (EPR) effect as well as glucose metabolism.